Target therapy versus dacarbazine in first-line treatment of advanced non-surgical and metastatic melanoma: budget impact analysis from the perspective of the Brazilian National Health System, 2018-2020.
Flávia de Miranda CorrêaRenata Leborato GuerraRicardo Ribeiro Alves FernandesMirian Carvalho de SouzaIvan Ricardo ZimmermannPublished in: Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil (2019)
the use of target therapy compared to dacarbazine implies an excessive impact on the budget, this bring unfovorable to its possible incorporation.